Bayer: a bitter pill to swallow

Credit of the month

com-1-gif

Bayer has been shaken by widespread litigation concerning its ill-fated anti-cholesterol drug, Baycol. Despite winning its first major US court case, in Corpus Christi, Texas, a factor that softened market sentiment towards Bayer, future lawsuits are still a big thorn in the German company’s side. The victory does set a favourable precedent, but the decision should not be viewed as the end of Bayer’s troubles, as each individual case differs in its circumstances.

The German pharmaceuticals

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact info@risk.net or view our subscription options here: http://subscriptions.risk.net/subscribe

You are currently unable to copy this content. Please contact info@risk.net to find out more.

Sorry, our subscription options are not loading right now

Please try again later. Get in touch with our customer services team if this issue persists.

New to Risk.net? View our subscription options

If you already have an account, please sign in here.

You need to sign in to use this feature. If you don’t have a Risk.net account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here